Shares of Clover Health Investments, Corp. (NASDAQ:CLOV – Get Free Report) have earned a consensus rating of “Hold” from the five brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $4.3333.
Several research analysts have weighed in on CLOV shares. Canaccord Genuity Group raised their price objective on shares of Clover Health Investments from $4.20 to $5.50 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Clover Health Investments in a research report on Wednesday, June 24th. Wall Street Zen downgraded Clover Health Investments from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 16th. Finally, UBS Group boosted their price objective on Clover Health Investments from $4.75 to $5.00 and gave the company a “neutral” rating in a report on Thursday, August 6th.
Read Our Latest Report on Clover Health Investments
Clover Health Investments Price Performance
Clover Health Investments (NASDAQ:CLOV – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of $0.04 by $0.01. The company had revenue of $743.17 million during the quarter, compared to analysts’ expectations of $728.27 million. Clover Health Investments had a negative return on equity of 4.20% and a negative net margin of 0.74%.
Insiders Place Their Bets
In related news, VP Joseph Frank Oldakowski sold 12,102 shares of the firm’s stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $4.86, for a total transaction of $58,815.72. Following the transaction, the vice president directly owned 299,067 shares in the company, valued at $1,453,465.62. This trade represents a 3.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Conrad Wai sold 220,426 shares of Clover Health Investments stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $3.99, for a total transaction of $879,499.74. Following the completion of the transaction, the chief executive officer directly owned 1,390,056 shares of the company’s stock, valued at approximately $5,546,323.44. This represents a 13.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 638,483 shares of company stock valued at $3,035,848 in the last quarter. Insiders own 23.51% of the company’s stock.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Abel Hall LLC bought a new stake in shares of Clover Health Investments during the 4th quarter valued at about $27,000. Allworth Financial LP lifted its holdings in Clover Health Investments by 218.9% in the third quarter. Allworth Financial LP now owns 9,509 shares of the company’s stock worth $29,000 after acquiring an additional 6,527 shares during the last quarter. Quadrature Capital Ltd bought a new position in Clover Health Investments in the fourth quarter worth about $29,000. Schonfeld Strategic Advisors LLC acquired a new position in Clover Health Investments in the fourth quarter valued at approximately $29,000. Finally, Envestnet Asset Management Inc. acquired a new position in Clover Health Investments in the second quarter valued at approximately $31,000. 19.77% of the stock is currently owned by institutional investors.
About Clover Health Investments
Clover Health Investments is a technology-driven healthcare company specializing in Medicare Advantage plans for senior populations. The company combines insurance coverage with a proprietary software platform to improve care coordination, outcomes tracking and cost management. By leveraging data analytics, Clover Health aims to deliver personalized care pathways and preventive interventions for its members.
At the core of Clover’s offering is its Clover Assistant platform, which aggregates clinical and claims data from multiple sources to create real-time insights for physicians and care teams.
Featured Stories
- Five stocks we like better than Clover Health Investments
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Clover Health Investments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clover Health Investments and related companies with MarketBeat.com's FREE daily email newsletter.
